3//SEC Filing
Royalty Pharma Investments 2019 ICAV 3
Accession 0000899243-22-005424
CIK 0001571498other
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 4:30 PM ET
Size
5.3 KB
Accession
0000899243-22-005424
Insider Transaction Report
Form 3
Epizyme, Inc.EPZM
Royalty Pharma Investments 2019 ICAV
Director10% Owner
Holdings
- 22,666,667
Common Stock
Footnotes (3)
- [F1]Reflects 22,666,667 shares of common stock acquired by Royalty Pharma Investments 2019 ICAV ("RPI 2019 ICAV") from the underwriter in an underwritten public offering conducted by the Issuer that closed on January 31, 2022.
- [F2]This Form 3 is being filed by RPI 2019 ICAV. RP Management, LLC ("RP Management"), as the manager of RPI 2019 ICAV, and Pablo G. Legorreta, as the manager of RP Management, may be deemed to have beneficial ownership under Section 13 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") of the securities beneficially owned by RPI 2019 ICAV. RP Management and Mr. Legorreta disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that RP Management and/or Mr. Legorreta are the beneficial owners thereof for purposes of Section 16 of the Exchange Act or for any other purpose.
- [F3]Mr. Legorreta serves on the board of directors of the Issuer as a representative of RPI 2019 ICAV. As such, RPI 2019 ICAV may be deemed to be a director by deputization of the Issuer for purposes of Section 16(b)-3(d) of the Exchange Act.
Documents
Issuer
Epizyme, Inc.
CIK 0001571498
Entity typeother
IncorporatedIreland
Related Parties
1- filerCIK 0001909645
Filing Metadata
- Form type
- 3
- Filed
- Feb 8, 7:00 PM ET
- Accepted
- Feb 9, 4:30 PM ET
- Size
- 5.3 KB